RxDoctor Payments Data

Charles Kim

Hematology & Oncology · Berkeley Heights, NJNPI 1699208074

Payments from drug & device makers

$2,280in general payments, 2019–2025

Across 55 payments — averaging $41.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Seagen Inc.$416
  • Rigel Pharmaceuticals, Inc.$250
  • Incyte Corporation$239
  • Eisai Inc.$193
  • Genentech USA, Inc.$191
  • Pfizer$186
  • plus $805 from 16 others

What the payments were for

  • Food & beverage$2,02689%
  • Education$25411%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,280 in reported general payments places this provider in the 35th percentile of 362 hematology & oncology providers in New Jersey.

See all hematology & oncology providers in New Jersey

Medicare billing

Part B allowed, 2024
$1,262,905
Medicare patients
375
Services billed
88,113

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide16$320,426
EliquisApixaban99$75,000
Abiraterone Acetate27$55,857
XareltoRivaroxaban21$15,491
Dexamethasone31$594
Anastrozole11$493
Ondansetron OdtOndansetron26$451
Prednisone36$191
Gabapentin18$114
Acyclovir19$51
Potassium Chloride18$20

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$43$320,42616 claims
PfizerEliquis$186$75,00099 claims
Johnson & JohnsonXarelto$18$15,49121 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 362 hematology & oncology providers in New Jersey.

Other hematology & oncology in Berkeley Heights

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →